Join Abzena and BioSpring Partners for an expert panel webinar on Dec. 5th at 10am EST / 3pm GMT discussing strategies that de-risk and accelerate the development of Antibody Drug Conjugates (ADCs), Oligonucleotides and Radioconjugates.
Moving a new biologic or bioconjugate program forward from discovery to market can be a challenging and cumbersome process. The complexity of drug design, in particular ADCs, and considerable technical, safety, stability and scalability challenges make it incredibly difficult for developers to navigate the development pathway with speed and ease, while still ensuring an effective, high-quality product.
With the stakes high, having trusted and experienced guidance at each stage of development can help streamline the pathway from discovery towards IND, and beyond. Over the past 20 years, Abzena has helped hundreds of customers achieve their regulatory milestones. By supporting customers with extensive scientific knowledge, technical expertise and integrated services that span the entire development pathway, they employ de-risking strategies that greatly improve both clinical and commercial outcomes for biologic and bioconjugate drug programs.
Join Abzena’s CEO, Matt Stober, CSO, Dr. Campbell Bunce, CTO, Dr. Louise Duffy, and Biospring Partners’ Michelle Detwiler for a live Q&A panel discussion where they share their expert insights around the challenges and considerations that drug developers face in early development. Covering topics ranging from developability assessments and lead candidate selection to risk mitigation strategies for tech transfer and scale-up, they will answer your questions on how to successfully move your program forward to patients faster.
About Our Panelists
Matthew Stober, CEO at Abzena
Matthew has over 30 years of experience at large, multinational pharmaceutical organizations, in manufacturing operational roles. Matthew has previously held senior executive positions at Novartis Vaccines, Smith and Nephew and Hospira where he served as Global Head of Operations, President of Operations, and Senior Vice President of Operations respectively. His deep and extensive operational experience has been consolidated from senior positions at companies including GlaxoSmithKline, Merck and Pfizer.
Matthew holds various Board positions including current appointments at X-Vax Technology, Istari Oncology and Castlevax.
He holds a B.S. in chemical engineering from Villanova University, PA, USA.
Dr Louise Duffy, CTO at Abzena
With a career spanning over 30 years, Louise has deep expertise in the development, technology transfer, and supply of biopharmaceuticals, vaccines, and cell & gene therapies. She has in-depth experience in the development of strategic CMC approaches to support successful global regulatory inspections and filings such as INDs, IMPDs, BLA, and MAAs.
In her current role, Louise is responsible for leading and driving Abzena’s technical CMC strategy, providing technical and CMC regulatory leadership and guidance to project teams while working collaboratively with clients for project success. Prior to joining Abzena in 2020 she was an independent consultant in biopharmaceuticals and cell and gene therapies and has held senior leadership roles in GlaxoSmithKline as VP & Global Supply Chain Head, Biopharmaceuticals and Janssen R&D (J&J) as VP & Global Head, Strategic Sciences.
Louise contributes and speaks at organizations including BioPhorum, PDA and ISPE. Louise is on multiple scientific advisory panels.
Louise holds a Ph.D. and a M.Sc. in Chemical Engineering from Imperial College, London, and a B.Sc. in Chemistry and Biochemistry from the University of British Columbia, Vancouver, Canada.
Dr Campbell Bunce, CSO at Abzena
Campbell has over 25 years of experience working in the biotech and diagnostics sectors. As the current CSO and Cambridge Site Head, he leads a talented team of scientists across a diverse range of expertise and capabilities to support drug discovery, design, and developability, and cell line development.
He’s responsible for ensuring that Abzena’s strong innovation focus and depth of scientific expertise is maintained through technological developments and works in partnership with clients to design and deliver solutions that support their program needs.
Before joining Abzena in 2015, he held multiple positions of increasing responsibility in Biotech including Head of Cellular Immunology at Cantab Pharmaceuticals, Director of Programs at Piramed Pharma, and R&D Director at Immune Targeting systems.
Throughout his career he has applied innovative solutions for the design, manufacture and clinical evaluation of novel products including vaccines, biologics, and small molecules in multiple therapeutic areas. These include inflammation, cancer, infectious disease, and addiction.
Campbell has a Ph.D. in Immunology from the University of Manchester, UK, an Executive MBA from Judge Business School, Cambridge University, UK and has published a number of papers on cell-mediated immunity, immunotherapy and vaccines.